The CARI guidelines. Pharmacological approaches to preventing vascular access failure.
Polkinghorne
Kevan
K
D000925:Anticoagulants / Q000627:therapeutic use*; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects / Q000592:standards; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000592:standards; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000592:standards; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D016896:Treatment Outcome; D014654:Vascular Patency / Q000187:drug effects*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors